Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%

/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation...

Related Keywords

Israel ,Italy ,Spain ,Valencia ,Carabobo ,Venezuela ,China ,Israeli ,Icecure Prosense ,Todd Kehrli ,Michael Polyviou ,Azienda Ospedaliero Universitaria Careggi ,Eyal Shamir ,Icecure Medical Ltd ,Company Annual Report On Form ,European Society Of Breast Imaging ,European Society ,Breast Imaging ,Scientific Meeting ,Principal Investigator ,Diagnostic Senology Unit ,Cure Medical ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,